Project Details
Description
A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
| Status | Finished |
|---|---|
| Effective start/end date | 12/6/13 → 12/30/18 |
Funding
- ASTELLAS PHARMA US, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.